Other formats:
BibTeX
LaTeX
RIS
@proceedings{1787324,
author = {Vrábel, Dávid and Gregorová, Jana and Sedlaříková, Lenka and Almáši, Martina and Bezděková, Renata and Štork, Martin and Krejčí, Marta and Adam, Zdeněk and Pour, Luděk and Hajek, Roman and Ševčíková, Sabina},
booktitle = {60th Annual Meeting of the American-Society-of-Hematology (ASH)},
doi = {http://dx.doi.org/10.1182/blood-2018-99-114793},
keywords = {cell-free dna; multiple myeloma; neoplasms; immunoglobulin heavy chains; polymerase chain reaction; liquid biopsy; massively-parallel genome sequencing; molecule; biopsy; bone marrow specimen},
language = {eng},
title = {Tumor Specific cfDNA Predicts Treatment Response of Multiple Myeloma Patients},
url = {https://ashpublications.org/blood/article/132/Supplement%201/3188/263958/Tumor-Specific-cfDNA-Predicts-Treatment-Response},
year = {2018}
}
TY - CONF
ID - 1787324
AU - Vrábel, Dávid - Gregorová, Jana - Sedlaříková, Lenka - Almáši, Martina - Bezděková, Renata - Štork, Martin - Krejčí, Marta - Adam, Zdeněk - Pour, Luděk - Hajek, Roman - Ševčíková, Sabina
PY - 2018
TI - Tumor Specific cfDNA Predicts Treatment Response of Multiple Myeloma Patients
KW - cell-free dna
KW - multiple myeloma
KW - neoplasms
KW - immunoglobulin heavy chains
KW - polymerase chain reaction
KW - liquid biopsy
KW - massively-parallel genome sequencing
KW - molecule
KW - biopsy
KW - bone marrow specimen
UR - https://ashpublications.org/blood/article/132/Supplement%201/3188/263958/Tumor-Specific-cfDNA-Predicts-Treatment-Response
N2 - Great progress achieved in treatment of multiple myeloma (MM) over the past decade changed overall perception of importance of minimal residual disease (MRD) assessment. Since new drugs induce deep responses, MRD must be evaluated using sensitive techniques, such as allele specific PCR (ASO-PCR), next-generation sequencing (NGS) or flow cytometry. MM is a genetically heterogeneous cancer of plasma cells characterized by multiple focal lesions in the bone marrow (BM). Hence, a single-site biopsy can create a sampling bias. In spite of this, BM samples are typically used for MRD analysis, but currently an alternative approach called liquid biopsies, which utilizes body fluids for analysis of various molecules and cells, is intensively studied. Cell-free DNA (cfDNA) as one type of the molecule which can be analyzed using liquid biopsy approach showed promising results previously. In our study, patient-specific, clonotypic rearrangement of immunoglobulin heavy chain (IgH) gene, identified in bone marrow samples, was used for qPCR analysis of cfDNA samples from peripheral blood. We demonstrate that dynamics and quantity of patient-specific, clonotypic IgH rearrangement found in cfDNA can predict the outcomes and response of MM patients.
ER -
VRÁBEL, Dávid, Jana GREGOROVÁ, Lenka SEDLAŘÍKOVÁ, Martina ALMÁŠI, Renata BEZDĚKOVÁ, Martin ŠTORK, Marta KREJČÍ, Zdeněk ADAM, Luděk POUR, Roman HAJEK and Sabina ŠEVČÍKOVÁ. Tumor Specific cfDNA Predicts Treatment Response of Multiple Myeloma Patients. In \textit{60th Annual Meeting of the American-Society-of-Hematology (ASH)}. 2018. ISSN~0006-4971. Available from: https://dx.doi.org/10.1182/blood-2018-99-114793.
|
